METiS Pharmaceuticals has established a strategic alliance with Deerfield Management, a professional investment institution in the global life sciences and healthcare sectors. The two parties will jointly develop a new generation of in vivo protein therapeutics and immunotherapies, while advancing the global commercialization of their collaborative pipeline products. METiS Pharmaceuticals will contribute its proprietary technologies in areas such as AI-driven protein engineering, while Deerfield will leverage its extensive industry experience to deeply participate in the global clinical development and business expansion of METiS's self-developed AI nano-delivery platform, NanoForge, along with its driven solutions and core pipeline projects. The collaboration covers a leading T-cell engager project, with Deerfield actively exploring potential licensing and development opportunities to advance it into IND-supportive studies and clinical development stages. Deerfield boasts extensive experience in the healthcare sector, having invested in over 200 companies and managing assets exceeding $16 billion.